Imperial College London

ProfessorWendyBarclay

Faculty of MedicineDepartment of Infectious Disease

Action Medical Research Chair Virology. Head of Department
 
 
 
//

Contact

 

+44 (0)20 7594 5035w.barclay

 
 
//

Location

 

416Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Drake:2021:10.1016/S0140-6736(21)00799-6,
author = {Drake, TM and Riad, AM and Fairfield, CJ and Egan, C and Knight, SR and Pius, R and Hardwick, HE and Norman, L and Shaw, CA and McLean, KA and Thompson, AAR and Ho, A and Swann, OV and Sullivan, M and Soares, F and Holden, KA and Merson, L and Plotkin, D and Sigfrid, L and de, Silva TI and Girvan, M and Jackson, C and Russell, CD and Dunning, J and Solomon, T and Carson, G and Olliaro, P and Nguyen-Van-Tam, JS and Turtle, L and Docherty, AB and Openshaw, PJ and Baillie, JK and Harrison, EM and Semple, MG and ISARIC4C, investigators},
doi = {10.1016/S0140-6736(21)00799-6},
journal = {The Lancet},
pages = {223--237},
title = {Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study},
url = {http://dx.doi.org/10.1016/S0140-6736(21)00799-6},
volume = {398},
year = {2021}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BACKGROUND: COVID-19 is a multisystem disease and patients who survive might have in-hospital complications. These complications are likely to have important short-term and long-term consequences for patients, health-care utilisation, health-care system preparedness, and society amidst the ongoing COVID-19 pandemic. Our aim was to characterise the extent and effect of COVID-19 complications, particularly in those who survive, using the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK. METHODS: We did a prospective, multicentre cohort study in 302 UK health-care facilities. Adult patients aged 19 years or older, with confirmed or highly suspected SARS-CoV-2 infection leading to COVID-19 were included in the study. The primary outcome of this study was the incidence of in-hospital complications, defined as organ-specific diagnoses occurring alone or in addition to any hallmarks of COVID-19 illness. We used multilevel logistic regression and survival models to explore associations between these outcomes and in-hospital complications, age, and pre-existing comorbidities. FINDINGS: Between Jan 17 and Aug 4, 2020, 80388 patients were included in the study. Of the patients admitted to hospital for management of COVID-19, 49·7% (36367 of 73197) had at least one complication. The mean age of our cohort was 71·1 years (SD 18·7), with 56·0% (41025 of 73197) being male and 81·0% (59289 of 73197) having at least one comorbidity. Males and those aged older than 60 years were most likely to have a complication (aged ≥60 years: 54·5% [16579 of 30416] in males and 48·2% [11707 of 24288] in females; aged <60 years: 48·8% [5179 of 10609] in males and 36·6% [2814 of 7689] in females). Renal (24·3%, 17752 of 73197), complex respiratory (18·4%, 13486 of 73197), and systemic (16·3%, 11895 of 73197) complications were
AU - Drake,TM
AU - Riad,AM
AU - Fairfield,CJ
AU - Egan,C
AU - Knight,SR
AU - Pius,R
AU - Hardwick,HE
AU - Norman,L
AU - Shaw,CA
AU - McLean,KA
AU - Thompson,AAR
AU - Ho,A
AU - Swann,OV
AU - Sullivan,M
AU - Soares,F
AU - Holden,KA
AU - Merson,L
AU - Plotkin,D
AU - Sigfrid,L
AU - de,Silva TI
AU - Girvan,M
AU - Jackson,C
AU - Russell,CD
AU - Dunning,J
AU - Solomon,T
AU - Carson,G
AU - Olliaro,P
AU - Nguyen-Van-Tam,JS
AU - Turtle,L
AU - Docherty,AB
AU - Openshaw,PJ
AU - Baillie,JK
AU - Harrison,EM
AU - Semple,MG
AU - ISARIC4C,investigators
DO - 10.1016/S0140-6736(21)00799-6
EP - 237
PY - 2021///
SN - 0140-6736
SP - 223
TI - Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
T2 - The Lancet
UR - http://dx.doi.org/10.1016/S0140-6736(21)00799-6
UR - https://www.ncbi.nlm.nih.gov/pubmed/34274064
UR - http://hdl.handle.net/10044/1/90609
VL - 398
ER -